PEHL MICHAEL F. 4/A
4/A · IMMUNOMEDICS INC · Filed Dec 22, 2017
Insider Transaction Report
Form 4/AAmended
IMMUNOMEDICS INCIMMU
PEHL MICHAEL F.
DirectorPresident and CEO
Transactions
- Award
Stock Options (right to buy)
2017-12-07+320,139→ 320,139 totalExercise: $11.86Exp: 2024-12-07→ Common Stock, par value $0.01 per share (320,139 underlying) - Award
Stock Options (right to buy)
2017-12-07+119,237→ 119,237 totalExercise: $11.86Exp: 2024-12-07→ Common Stock, par value $0.01 per share (119,237 underlying)
Footnotes (4)
- [F1]The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.
- [F2]The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 151,678 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $23.72 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 168,461 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $35.58 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date.
- [F3]If the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, and to the extent such performance-based vesting criteria is subsequently attained, the applicable tranche of stock options may vest on the date such criteria is met.
- [F4]The purpose of this amendment is to correct the number of shares reported in Table II, Column 5, Column 7 and Column 9.